Sugi Predict

Sugi Predict / Compounds / SCHEMBL850463

SCHEMBL850463

SCHEMBL850463

CC(=O)Nc1cc(C)c(Br)c(C)c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 1/20 0.54
▸ ALDH1A1 P00352 5/20 0.49
▸ MEN1 O00255 3/20 0.48
▸ KMT2A Q03164 3/20 0.48
▸ TDP1 Q9NUW8 2/20 0.48
▸ HSD17B10 Q99714 2/20 0.47
▸ GAA P10253 2/20 0.46
▸ IDO1 P14902 1/20 0.45
▸ SMN1; SMN2 Q16637 2/20 0.45
▸ HTT P42858 1/20 0.45
▸ L3MBTL1 Q9Y468 1/20 0.45
▸ NAPRT Q6XQN6 1/20 0.45
▸ MAPT P10636 2/20 0.44
▸ PKM P14618 2/20 0.44
▸ CA12 O43570 1/20 0.43
▸ BRD4 O60885 1/20 0.43
▸ NR1I2 O75469 1/20 0.43
▸ CA1 P00915 1/20 0.43
▸ CA2 P00918 1/20 0.43
▸ MB P02144 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6864047 0.84 ALDH1A1 (0.41) LMNAALDH1A1MEN1KMT2AGAA
SCHEMBL3030037 0.84 LMNA (0.60) LMNAALDH1A1MEN1KMT2ATDP1
SCHEMBL31083015 0.84 ALDH1A1 (0.44) LMNAALDH1A1MEN1KMT2ASMN1; SMN2
SCHEMBL27670903 0.81 KIF11 (0.46) LMNAALDH1A1MEN1KMT2AGAA
SCHEMBL18751502 0.80 LMNA (0.52) LMNAALDH1A1MEN1KMT2ATDP1
SCHEMBL2552398 0.80 LMNA (0.61) LMNAALDH1A1MEN1KMT2ATDP1
SCHEMBL879705 0.79 SMN1; SMN2 (0.47) LMNAALDH1A1MEN1KMT2ASMN1; SMN2
SCHEMBL11564168 0.79 LMNA (0.46) LMNAALDH1A1MEN1KMT2ATDP1
SCHEMBL16302253 0.78 LMNA (0.54) LMNAALDH1A1MEN1KMT2ATDP1
SCHEMBL10890401 0.78 LMNA (0.54) LMNAALDH1A1MEN1KMT2ATDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3543242-B1 8,9-DIHYDROIMIDAZOLE[1,2-A]PYRIMIDO[5,4-E]PYRIMIDINE-5(6H)-KETONE COMPOUND IMPACT THERAPEUTICS SHANGHAI INC (CN) 2024-01-03 — — EP disclosed
US-11345711-B2 8,9-dihydroimidazo[1,2-a]pyrimido[5,4-e]pyrimidin-5(6H)-ones Impact Therapeutics (Shanghai), Inc (CN) 2022-05-31 — — US disclosed
CN-109906227-B 8, 9-dihydroimidazo [1,2-a ] pyrimido [5,4-e ] pyrimidin-5 (6H) -ones 上海瑛派药业有限公司 2022-03-11 — — CN disclosed
US-20200385394-A1 8,9-DIHYDROIMIDAZO[1,2-a]PYRIMIDO[5,4-e]PYRIMIDIN-5(6H)-ONES Impact Therapeutics (Shanghai), Inc (CN) 2020-12-10 — — US disclosed
US-10703759-B2 8,9-dihydroimidazo[1,2-a]pyrimido[5,4-e]pyrimidin-5(6H)-ones IMPACT THERAPEUTICS, INC (CN) 2020-07-07 — — US disclosed
US-20190308984-A1 8,9-DIHYDROIMIDAZO[1,2-a]PYRIMIDO[5,4-e]PYRIMIDIN-5(6H)-ONES Impact Therapeutics (Shanghai), Inc (CN) 2019-10-10 — — US disclosed
EP-3543242-A1 8,9-DIHYDROIMIDAZOLE[1,2-A]PYRIMIDO[5,4-E]PYRIMIDINE-5(6H)-KETONE COMPOUND Impact Therapeutics, Inc (CN) 2019-09-25 — — EP disclosed
US-9487517-B2 Spiroimidazolone derivative CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2016-11-08 — — US disclosed
US-9487517-B2 Spiroimidazolone derivative CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2016-11-08 — — US disclosed
US-9487517-B2 Spiroimidazolone derivative CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2016-11-08 — — US disclosed
US-20110046133-A1 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2011-02-24 — — US disclosed
WO-2010126030-A1 SPIROIMIDAZOLONE DERIVATIVE 中外製薬株式会社 (JP) 2010-11-04 — — WO disclosed
CN-101553468-A Organic compounds NOVARTIS AG (CH) 2009-10-07 — — CN disclosed
EP-2074089-A2 ORGANIC COMPOUNDS Novartis AG (CH) 2009-07-01 — — EP disclosed
CN-101389335-A Thiadiazole compounds and methods of use. AMGEN INC (US) 2009-03-18 — — CN disclosed
CN-101374813-A Arylsulfonamide and sulfonyl compounds as PPAR modulators and methods of treating metabolic disorders KALYPSYS INC (US) 2009-02-25 — — CN disclosed
WO-2008048991-A2 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2008-04-24 — — WO disclosed
EP-1735280-A1 ARYL SULFONAMIDE AND SULFONYL COMPOUNDS AS MODULATORS OF PPAR AND METHODS OF TREATING METABOLIC DISORDERS Kalypsys, Inc. (US) 2006-12-27 — — EP disclosed
WO-2005115983-A1 ARYL SULFONAMIDE AND SULFONYL COMPOUNDS AS MODULATORS OF PPAR AND METHODS OF TREATING METABOLIC DISORDERS KALYPSYS, INC. (US) 2005-12-08 — — WO disclosed
US-20050234046-A1 Aryl sulfonamide and sulfonyl compounds as modulators of PPAR and methods of treating metabolic disorders KALYPSYS, INC. (US) 2005-10-20 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050234046-A1 Aryl sulfonamide and sulfonyl compounds as modulators of PPAR and methods of treating metabolic disorders PPARA, PPARG, PPARD LMNA 3289/4885ALDH1A1 883/4885MEN1 4791/4885
US-20190308984-A1 8,9-DIHYDROIMIDAZO[1,2-a]PYRIMIDO[5,4-e]PYRIMIDIN-5(6H)-ONES WEE1, WEE2, CCNE1 LMNA 3833/4885ALDH1A1 1361/4885MEN1 1992/4885
US-11345711-B2 8,9-dihydroimidazo[1,2-a]pyrimido[5,4-e]pyrimidin-5(6H)-ones WEE1, WEE2, CCNE1 LMNA 3833/4885ALDH1A1 1361/4885MEN1 1992/4885
US-10703759-B2 8,9-dihydroimidazo[1,2-a]pyrimido[5,4-e]pyrimidin-5(6H)-ones WEE1, WEE2, CCNE1 LMNA 3833/4885ALDH1A1 1361/4885MEN1 1992/4885
US-20110046133-A1 ORGANIC COMPOUNDS DGAT1, DGAT2, SOAT1 LMNA 986/4885ALDH1A1 44/4885MEN1 3613/4885
US-20200385394-A1 8,9-DIHYDROIMIDAZO[1,2-a]PYRIMIDO[5,4-e]PYRIMIDIN-5(6H)-ONES WEE1, WEE2, CCNE1 LMNA 3833/4885ALDH1A1 1361/4885MEN1 1992/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.